July 2018
Volume 59, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2018
Contrast sensitivity in patients with branch retinal vein occlusion following intravitreal ranibizumab injection
Author Affiliations & Notes
  • Yoshimi Sugiura
    Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
  • Fumiki Okamoto
    Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
  • Tomoya Murakami
    Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
  • Shohei Morikawa
    Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
  • Takahiro Hiraoka
    Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
  • Tetsuro Oshika
    Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
  • Footnotes
    Commercial Relationships   Yoshimi Sugiura, None; Fumiki Okamoto, None; Tomoya Murakami, None; Shohei Morikawa, None; Takahiro Hiraoka, None; Tetsuro Oshika, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4275. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yoshimi Sugiura, Fumiki Okamoto, Tomoya Murakami, Shohei Morikawa, Takahiro Hiraoka, Tetsuro Oshika; Contrast sensitivity in patients with branch retinal vein occlusion following intravitreal ranibizumab injection. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4275.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate contrast sensitivity in patients with branch retinal vein occlusion (BRVO) following intravitreal ranibizumab injection (IVR), and to investigate the relationship between contrast sensitivity and retinal microstructure.

Methods : We included 27 eyes of 27 patients with macular edema caused by BRVO who were followed up for 6 months after treatment. All patients were treatment naïve with no history of treatment with intravitreal anti-VEGF injection, intraocular corticosteroids, retinal photocoagulation, or pars plana vitrectomy. We measured best-corrected visual acuity (BCVA), letter contrast sensitivity (LC), and 10% low contrast visual acuity (LCVA). All tests were performed before and 1, 2, 3, 4, 5, and 6 months after treatment. Based on optical coherence tomography (OCT) images, we assessed central retinal thickness (CRT), presence of serous retinal detachment (SRD), and status of the external limiting membrane (ELM) and ellipsoid zone (EZ).

Results : IVR treatment significantly improved contrast sensitivity (LC: P < 0.0001, LCVA: P = 0.0001) as well as BCVA (P < 0.0005) and CRT (P < 0.0001). LC and LCVA at 6 months after treatment were significantly correlated with SRD before treatment.
At 6 months after treatment, LC showed a significant correlation with absence of the ELM and EZ, while LCVA was significantly correlated with CRT. In patients with good baseline BCVA, LC and LCVA showed significant improvements (P < 0.05, P < 0.01) by IVR although their BCVA did not change. In patients with poor improvement in BCVA, LC and LCVA also showed significant improvements (P = 0.001, P < 0.005).

Conclusions : IVR treatment for BRVO improved not only BCVA but also contrast sensitivity. Even in patients without any improvement in visual acuity, contrast sensitivity improved by IVR.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×